镥-177 PSMA放射配体治疗用于经一线ARPI治疗后未接受紫杉烷类化疗的转移性去势抵抗性前列腺癌一线及二线治疗
该回顾性单中心研究基于FRAMCAP数据库,分析269例经ARPI治疗后未接受紫杉烷类化疗的mCRPC患者,11%接受镥-177 PSMA放射配体治疗,57%接受ARPI,33%接受多西他赛。Lu-PSMA组相比ARPI组无进展生存期(13.3 vs 8.2个月)和总生存期(68.9 vs 39.1个月)数值上更优但未达统计学显著,多因素校正后差异显著;相比多西他赛组,Lu-PSMA组PFS和OS均显著更优。作者认为Lu-PSMA可作为早期mCRPC治疗选择。
要点
- 经ARPI治疗后未接受紫杉烷类化疗的mCRPC患者中,Lu-PSMA组PFS 13.3个月 vs ARPI组8.2个月,HR 0.70,p=0.16,未达统计学显著。
- Lu-PSMA组OS 68.9个月 vs ARPI组39.1个月,HR 0.64,p=0.2,未达统计学显著;多因素校正后Lu-PSMA相比ARPI的PFS和OS均显著更优(均p<0.05)。
- Lu-PSMA组相比多西他赛组PFS 13.3 vs 8.1个月(HR 0.46)和OS 68.9 vs 27.3个月(HR 0.34)均显著更优(均p<0.01)。
核心结论
- 该回顾性单中心研究提示,经ARPI治疗后未接受紫杉烷类化疗的mCRPC患者中,Lu-PSMA治疗相比ARPI或多西他赛提供显著更优的PFS和OS结局,作者认为可考虑作为早期mCRPC治疗选择。
研究设计与样本
- 回顾性单中心研究,基于FRAMCAP数据库,纳入269例经ARPI治疗后未接受紫杉烷类化疗的mCRPC患者,比较Lu-PSMA与ARPI或多西他赛的PFS和OS。
主要发现
- 269例患者中,11%接受Lu-PSMA作为一线/二线mCRPC治疗,57%接受ARPI,33%接受多西他赛。
- Lu-PSMA组与ARPI组基线大多无显著差异,但Lu-PSMA组相比多西他赛组年龄显著更大、接受系统治疗更少、ECOG 1-2比例更高。
- Lu-PSMA组相比ARPI组PFS 13.3 vs 8.2个月(HR 0.70,p=0.16),OS 68.9 vs 39.1个月(HR 0.64,p=0.2),数值上更优但未达统计学显著。
- 多因素Cox回归模型中,Lu-PSMA相比ARPI的PFS和OS均显著更优(均p<0.05)。
- Lu-PSMA组相比多西他赛组PFS 13.3 vs 8.1个月(HR 0.46)和OS 68.9 vs 27.3个月(HR 0.34)均显著更优(均p<0.01),OS优势在多因素校正后仍存在(p<0.01)。
临床怎么用
- 作者认为,经ARPI治疗后未接受紫杉烷类化疗的mCRPC患者中,Lu-PSMA治疗可考虑作为早期mCRPC治疗选择。
局限性
- 该研究为回顾性单中心研究。
- 研究包含相当比例对Lu-PSMA有治疗偏好的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lutetium-177 Prostate-specific membrane antigen (Lu-PSMA) radioligand therapy is EMA-approved for metastatic castration resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition (ARPI) and taxan-based chemotherapy. However, its effect in taxan-naïve patients is under current investigation. METHODS: We relied on the FRAMCAP database to elaborate Lu-PSMA therapy outcomes of progression-free (PFS) and overall (OS) in taxan-naïve mCRPC patients after previous ARPI treatment. Comparison was made against current standard of care with ARPI or docetaxel, irrespective of the previous used staging modality. RESULTS: Of 269 patients, 11% received Lu-PSMA in first/second-line mCRPC vs. 57% ARPI vs. 33% docetaxel. Mostly no significant baseline differences between Lu-PSMA and ARPI patients were observed, while Lu-PSMA patients were significantly older, received less systematic treatments and ECOG1-2 proportions were higher, relative to docetaxel patients. In PFS (13.3 vs. 8.2 months, hazard ratio [HR]: 0.70, p = 0.16) and OS analyses (68.9 vs. 39.1 months, HR: 0.64, p = 0.2), Lu-PSMA was numerically more favorable than ARPI. In additional multivariable Cox regression models, Lu-PSMA was significant better regarding PFS and OS, relative to ARPI (both p < 0.05). Compared to docetaxel, also significant better PFS (13.3 vs. 8.1 months, HR: 0.46) and OS (68.9 vs. 27.3 months, HR: 0.34, both p < 0.01) was observed for Lu-PSMA treatment. The OS advantage was also observed after multivariable adjustment (p < 0.01). CONCLUSION: This retrospective single-center study including a substantial proportion of patients with treatment preference for Lu-PSMA suggests that Lu-PSMA therapy provides significantly more favorable PFS and OS outcomes in taxan-naïve mCRPC patients after previous ARPI treatment, relative to ARPI or docetaxel treatment and may be considered as an early mCRPC treatment option.
引用
- Wenzel M, Hoeh B, Siech C, et al. Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy. Eur J Nucl Med Mol Imaging. 2025. PMID: 39804375. doi:10.1007/s00259-025-07076-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。